Related references
Note: Only part of the references are listed.Institutional review board training when patients and community members are engaged as researchers
John M. Westfall et al.
FAMILY PRACTICE (2017)
Appraisal assessment in patient-reported outcome research: methods for uncovering the personal context and meaning of quality of life
Carolyn E. Schwartz et al.
QUALITY OF LIFE RESEARCH (2017)
Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease
Fabio Efficace et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Minimal important differences for fatigue patient reported outcome measures-a systematic review
Asa Nordin et al.
BMC MEDICAL RESEARCH METHODOLOGY (2016)
Measuring health-related quality of life in patients with conservatively managed stage 5 chronic kidney disease: limitations of the Medical Outcomes Study Short Form 36: SF-36
Gilli Erez et al.
QUALITY OF LIFE RESEARCH (2016)
Fatigue in immune thrombocytopenia
Quentin A. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Management of immune thrombocytopenia in adults: a population-based analysis of the French hospital discharge database from 2009 to 2012
Marc Michel et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study
Henrik Frederiksen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia
Nada Suvajdzic et al.
PLATELETS (2014)
Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care
David J. Kuter et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia
Donald M. Arnold et al.
BLOOD (2012)
The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim
Robert Deuson et al.
JOURNAL OF MEDICAL ECONOMICS (2012)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Fatigue in adult patients with primary immune thrombocytopenia
Julia L. Newton et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study
Gregory Cheng et al.
LANCET (2011)
Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials
Zeinab Hamidou et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
A point of minimal important difference (MID): a critique of terminology and methods
Madeleine T. King
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2011)
International consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan et al.
BLOOD (2010)
Health-related lifestyle in adults and children with primary immune thrombocytopenia (ITP)
Ameet Sarpatwari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Guidelines for improving the stringency of response shift research using the thentest
Carolyn E. Schwartz et al.
QUALITY OF LIFE RESEARCH (2010)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials
James N. George et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences
Susan D. Mathias et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives
Jacqueline A. Guidry et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura
Robert McMillan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey
Claire F. Snyder et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
Susan D. Mathias et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Making quality-of-life results more meaningful for clinicians
Madeleine T. King et al.
LANCET (2008)
Treatment of chronic immune thrombocytopenic purpura: the patients' perspective
Axel Matzdorff et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: Its development and validation
Susan D. Mathias et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
Health-related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China
Zeping Zhou et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
The pathogenesis of immune thrombocytopaenic purpura
N Cooper et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
The effect of antiplatelet autoantibodies on megakaryocytopoiesis
R McMillan et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?
N Cooper et al.
BLOOD (2002)
The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts
YC Cohen et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
Share Paper
